All News
Filter News
Found 808,690 articles
-
Xencor to Present at the Jefferies Virtual Healthcare Conference
5/27/2021
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:00 p.m. ET / 10:00 a.m. PT.
-
Yumanity Therapeutics to Present at Upcoming Virtual Investor Conferences - May 27, 2021
5/27/2021
Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the following virtual investor conferences in June.
-
Olympus Acquires Israeli Medical Device Company Medi-Tate to Drive Global Urology Business Growth
5/27/2021
Olympus Corporation (”Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced today that it has finalized the acquisition of Israeli medical device company Medi-Tate Ltd. (“Medi-Tate” – CEO: Ido Kilemnik) following the announcement of its decision to exercise the call option in February, 2021
-
Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology
5/27/2021
Series of preclinical studies demonstrate the therapeutic potential of CY6463, a first-in-class, CNS-penetrant sGC stimulator Oral, once-daily CY6463 is being developed for neurological diseases associated with cognitive impairment
-
Antengene Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome
5/27/2021
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced the dosing of the first patient in China in a Phase I/II trial (the HATCH trial) of eltanexor
-
TG Therapeutics to Present at Upcoming Investor Conferences - May 27, 2021
5/27/2021
TG Therapeutics, Inc. announced its participation at three upcoming virtual investor conferences.
-
Iterum Therapeutics Provides Update on NDA Review
5/27/2021
Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company participated in a late-cycle meeting with the U.S. Food and Drug Administration (“FDA”) yesterday.
-
August Bioservices Closes $23.6 Million Series A Extension to Expand U.S. Biopharma Manufacturing Capabilities
5/27/2021
August Bioservices,LLC, a contract development and manufacturing organization (CDMO) providing drug discovery, development, and pharmaceutical manufacturing services, closed a $23.6 million Series A extension, led by Polaris Partners, who joined existing investor Oak HC/FT.
-
AffaMed Therapeutics Announces Approval for the Phase IIb Clinical Study of AM006 in China for the Treatment of Parkinson's Disease
5/27/2021
AffaMed Therapeutics ("AffaMed"), a global clinical stage biopharmaceutical company dedicated to addressing critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, today announced that China's National Medical Products Administration (NMPA) has approved the Clinical Trial Application (CTA) for a Phase IIb global clinical trial led by AffaMed to evaluate the safety and efficacy of AM006
-
CareDx to Participate in Jefferies Healthcare Conference - May 27, 2021
5/27/2021
CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the Company plans to participate in the Jefferies Virtual Healthcare Conference.
-
CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application
5/27/2021
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precision medicines, today announced that a registrational clinical trial (GEMSTONE-301 study) of the anti-PD-L1 monoclonal antibody sugemalimab in patients with stage III NSCLC
-
EpimAb Biotherapeutics Appoints Jerry Su, Ph.D. as Chief Technology Officer
5/27/2021
EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibodies, today announced the appointment of Jerry Su, Ph.D. as the Chief Technology Officer of EpimAb.
-
DENTSPLY SIRONA Increases Quarterly Cash Dividend By 10%
5/27/2021
DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY), announced that its Board of Directors approved a 10% increase in the company’s quarterly dividend rate, from the previous rate of $0.10 per share of common stock to $0.11 per share. The dividend is payable on July 9, 2021 to holders of record as of June 25, 2021.
-
Neuroscientist from Université Laval, Dr. Steve Lacroix, wins prestigious award for spinal cord injury research
5/27/2021
Brain Canada and the Barbara Turnbull Foundation for Spinal Cord Research are pleased to announce that Dr. Steve Lacroix has been selected by an international panel to receive the 2020 Turnbull-Tator Award in Spinal Cord Injury and Concussion Research.
-
FDA Approves Biohaven's NURTEC® ODT (rimegepant) for Prevention: Now the First and Only Migraine Medication for both Acute and Preventive Treatment
5/27/2021
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that the U.S. Food and Drug Administration (FDA) has approved NURTEC® ODT (rimegepant 75 mg) for the preventive treatment of migraine
-
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1
5/27/2021
Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Zeposia® (ozanimod) 0.92 mg for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD).1
-
PPD Named ‘Most Innovative CRO’ by Triangle Business Journal
5/27/2021
PPD, Inc. (Nasdaq: PPD ) has been named “Most Innovative CRO” by North Carolina’s Triangle Business Journal , recognizing the global contract research organization’s strong performance in a year shaped by the COVID-19 pandemic.
-
Escient Pharmaceuticals Names Eric Deng, Ph.D., M.B.A. as Vice President, CMC Operations
5/27/2021
Escient Pharmaceuticals, Inc. , a clinical-stage, industry-leading platform company developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications, today announced that Eric Deng, Ph.D., M.B.A., has joined the company as Vice President, Chemistry, Manufacturing and Controls (CMC) Operations.
-
AIM ImmunoTech Announces Two Year Extension of Agreement with Shenzhen Smoore Technology Limited to Develop and Test a New Inhalation Delivery Device for Ampligen
5/27/2021
AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has entered into a two-year extension of its Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited (Smoore), a subsidiary of Smoore International Holdings Limited (HKEX: 6969), with the goal of developing Ampligen as a potential inhalation therapy for COVID-19 and potentially other respiratory viral diseases.
-
NexImmune Announces Formation of Scientific Advisory Board
5/27/2021
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Scientific Advisory Board (SAB).